This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/projekt/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n15http://linked.opendata.cz/ontology/domain/vavai/
n20http://linked.opendata.cz/resource/domain/vavai/zamer/
n19http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00179906%3A_____%2F11%3A10159060%21RIV14-MZ0-00179906/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n7http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00179906%3A_____%2F11%3A10159060%21RIV14-MZ0-00179906
rdf:type
skos:Concept n15:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.3324/haematol.2011.042937
dcterms:description
Background Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction. Design and Methods In this study, we employed real-time quantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol. Results We confirmed the previously published poor correlation between minimal residual disease in blood and marrow at early treatment time points, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold, range 0.04-8,293-fold). A greater involvement of peripheral blood at diagnosis was associated with a higher white blood cell count at diagnosis (P=0.003) and with enlargement of the spleen (P=0.0004) and liver (P=0.05). At day 15, a level of minimal residual disease in blood lower than 10(-4) was associated with an excellent 5-year relapse-free survival in 78 investigated patients (100% versus 69 +/- 7%; P=0.0003). Subgroups defined by the level of minimal residual disease in blood at day 15 (high-risk: }= 10(-2), intermediate-risk: <10(-2) and }= 10(-4), standard-risk: <10(-4)) partially correlated with bone marrow-based stratification described previously, but the risk groups did not match completely. No other time point analyses were predictive of outcome in peripheral blood, except for a weak association at day 8. Background Most minimal residual disease-directed treatment interventions in current treatment protocols for acute lymphoblastic leukemia are based on bone marrow testing, which is a consequence of previous studies showing the superiority of bone marrow over peripheral blood as an investigational material. Those studies typically did not explore the prognostic impact of peripheral blood involvement and lacked samples from very early time points of induction. Design and Methods In this study, we employed real-time quantitative polymerase chain reaction analysis to examine minimal residual disease in 398 pairs of blood and bone marrow follow-up samples taken from 95 children with B-cell precursor acute lymphoblastic leukemia treated with the ALL IC-BFM 2002 protocol. Results We confirmed the previously published poor correlation between minimal residual disease in blood and marrow at early treatment time points, with levels in bone marrow being higher than in blood in most samples (median 7.9-fold, range 0.04-8,293-fold). A greater involvement of peripheral blood at diagnosis was associated with a higher white blood cell count at diagnosis (P=0.003) and with enlargement of the spleen (P=0.0004) and liver (P=0.05). At day 15, a level of minimal residual disease in blood lower than 10(-4) was associated with an excellent 5-year relapse-free survival in 78 investigated patients (100% versus 69 +/- 7%; P=0.0003). Subgroups defined by the level of minimal residual disease in blood at day 15 (high-risk: }= 10(-2), intermediate-risk: <10(-2) and }= 10(-4), standard-risk: <10(-4)) partially correlated with bone marrow-based stratification described previously, but the risk groups did not match completely. No other time point analyses were predictive of outcome in peripheral blood, except for a weak association at day 8.
dcterms:title
Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis
skos:prefLabel
Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis Minimal residual disease in peripheral blood at day 15 identifies a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with superior prognosis
skos:notation
RIV/00179906:_____/11:10159060!RIV14-MZ0-00179906
n15:predkladatel
n16:ico%3A00179906
n3:aktivita
n10:Z n10:I n10:S n10:P
n3:aktivity
I, P(GP310/09/P058), P(NS10472), S, Z(MSM0021620813)
n3:cisloPeriodika
12
n3:dodaniDat
n9:2014
n3:domaciTvurceVysledku
n21:1228889
n3:druhVysledku
n17:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n19:predkladatel
n3:idSjednocenehoVysledku
212602
n3:idVysledku
RIV/00179906:_____/11:10159060
n3:jazykVysledku
n5:eng
n3:klicovaSlova
therapy; lineage; immunoglobulin; children; concerted action; aieop-bfm; bone-marrow; clinical-significance; receptor gene rearrangements; time quantitative pcr; childhood; day 15; minimal residual disease; peripheral blood; acute lymphoblastic leukemia
n3:klicoveSlovo
n4:day%2015 n4:receptor%20gene%20rearrangements n4:acute%20lymphoblastic%20leukemia n4:peripheral%20blood n4:lineage n4:concerted%20action n4:minimal%20residual%20disease n4:aieop-bfm n4:therapy n4:childhood n4:clinical-significance n4:children n4:bone-marrow n4:immunoglobulin n4:time%20quantitative%20pcr
n3:kodStatuVydavatele
IT - Italská republika
n3:kontrolniKodProRIV
[3F6D894A925F]
n3:nazevZdroje
Haematologica
n3:obor
n12:FG
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
16
n3:projekt
n11:GP310%2F09%2FP058 n11:NS10472
n3:rokUplatneniVysledku
n9:2011
n3:svazekPeriodika
96
n3:tvurceVysledku
Trka, Jan Hodonská, Ladislava Volejníková, Jana Blažek, Bohumír Černá, Zdeňka Procházková, Daniela Froňková, Eva Štěrba, Jaroslav Mihal, Vladimír Hak, Jiří Řezníčková, Leona Starý, Jan Mejstříková, Ester Jabali, Yahia Valová, Taťána Hrušák, Ondřej
n3:wos
000298544400015
n3:zamer
n20:MSM0021620813
s:issn
0390-6078
s:numberOfPages
7
n7:doi
10.3324/haematol.2011.042937